Leerink Partners Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Cuts Target Price to $18
TD Cowen Maintains Stoke Therapeutics(STOK.US) With Buy Rating
Stoke Therapeutics (STOK) Gets a Buy From TD Cowen
BTIG Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $29
H.C. Wainwright Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $35
Stoke Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Stoke Therapeutics, Maintains $35 Price Target
Buy Rating Affirmed for Stoke Therapeutics Amid Solid Q2 Performance and Regulatory Progress
Stoke Therapeutics Price Target Maintained With a $22.00/Share by Needham
Buy Rating Reaffirmed for Stoke Therapeutics Amidst Clinical Progress and Strong Financial Footing
Stoke Therapeutics Analyst Ratings
Wedbush Reiterates Outperform on Stoke Therapeutics, Maintains $17 Price Target
Stoke Therapeutics (STOK) Receives a Buy From Wedbush
Needham Reiterates Buy on Stoke Therapeutics, Maintains $22 Price Target
Stoke Therapeutics Analyst Ratings
Buy Rating Affirmed for Stoke Therapeutics Amid Strong Pipeline Prospects and Financial Stability
Canadian Investment Banking Group: Maintaining the Stoke Therapeutics (STOK.US) rating, adjusted from buy to buy rating, and adjusted the target price from $21.00 to $20.00.
Analysts Are Bullish on Top Healthcare Stocks: Stoke Therapeutics (STOK), Oric Pharmaceuticals (ORIC)
Stoke Therapeutics Analyst Ratings
Buy Rating for Stoke Therapeutics With Adjusted Price Target Amid Regulatory and Developmental Progress